DAVE vs. SRPT

Last updated Jun 4, 2026

DAVE (Dave Inc.) and SRPT (Sarepta Therapeutics, Inc.) are both stocks. DAVE operates in Software - Application (Technology), while SRPT operates in Biotechnology (Healthcare). Over the past 5 years, DAVE returned -4.66%/yr vs -25.96%/yr for SRPT. At a 0.19 correlation, their price movements are largely independent.

Performance

DAVE vs. SRPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Dave Inc. (DAVE) and Sarepta Therapeutics, Inc. (SRPT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, DAVE achieves a 12.61% return, which is significantly higher than SRPT's -24.54% return.

DAVE

• 1D: -6.56%
• 1M: -10.69%
• YTD: 12.61%
• 6M: 22.36%
• 1Y: 18.55%
• 3Y*: 250.41%
• 5Y*: -4.66%
• 10Y*: —

SRPT

• 1D: -0.06%
• 1M: -26.32%
• YTD: -24.54%
• 6M: -25.64%
• 1Y: -58.22%
• 3Y*: -49.37%
• 5Y*: -25.96%
• 10Y*: 0.42%

*Multi-year figures are annualized to reflect compound growth (CAGR)

DAVE vs. SRPT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DAVE Dave Inc.	12.61%	154.73%	936.61%	-9.64%	-97.17%	4.59%
SRPT Sarepta Therapeutics, Inc.	-24.54%	-82.30%	26.09%	-25.58%	43.90%	22.85%

Correlation

The correlation between DAVE and SRPT is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.22
Correlation (3Y) Calculated over the trailing 3-year period	0.23
Correlation (5Y) Calculated over the trailing 5-year period	0.19
Correlation (All Time) Calculated using the full available price history since Apr 27, 2021	0.19

Fundamentals

Market Cap DAVE : $3.59B SRPT : $1.98B
EPS DAVE : $15.54 SRPT : $0.60
PE Ratio DAVE : 16.04 SRPT : 27.06
PS Ratio DAVE : 6.55 SRPT : 0.81
PB Ratio DAVE : 17.62 SRPT : 1.32
Total Revenue (TTM) DAVE : $551.52M SRPT : $2.18B
Gross Profit (TTM) DAVE : $427.68M SRPT : $751.34M
EBITDA (TTM) DAVE : $165.95M SRPT : $107.91M

Return for Risk

DAVE vs. SRPT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DAVE

DAVE Risk / Return Rank: 49
DAVE Sharpe Ratio Rank: 50
DAVE Sortino Ratio Rank: 50
DAVE Omega Ratio Rank: 49
DAVE Calmar Ratio Rank: 50
DAVE Martin Ratio Rank: 49

SRPT

SRPT Risk / Return Rank: 17
SRPT Sharpe Ratio Rank: 16
SRPT Sortino Ratio Rank: 22
SRPT Omega Ratio Rank: 21
SRPT Calmar Ratio Rank: 10
SRPT Martin Ratio Rank: 18

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DAVE vs. SRPT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Dave Inc. (DAVE) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	DAVE	SRPT	Difference
Sharpe ratio Return per unit of total volatility	0.25	-0.56	+0.82
Sortino ratio Return per unit of downside risk	0.86	-0.36	+1.21
Omega ratio Gain probability vs. loss probability	1.11	0.94	+0.16
Calmar ratio Return relative to maximum drawdown	0.42	-0.81	+1.22
Martin ratio Return relative to average drawdown	0.75	-1.08	+1.82
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

DAVE vs. SRPT - Sharpe Ratio Comparison

The current DAVE Sharpe Ratio is 0.25, which is higher than the SRPT Sharpe Ratio of -0.56. The chart below compares the historical Sharpe Ratios of DAVE and SRPT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	DAVE	SRPT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.25	-0.56	+0.82
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.05	-0.37	+0.33
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.01	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.05	-0.03	-0.01

Drawdowns

DAVE vs. SRPT - Drawdown Comparison

The maximum DAVE drawdown since its inception was -99.01%, roughly equal to the maximum SRPT drawdown of -98.17%. Use the drawdown chart below to compare losses from any high point for DAVE and SRPT.

Drawdown Indicators

	DAVE	SRPT	Difference
Max Drawdown Largest peak-to-trough decline	-99.01%	-98.17%	-0.84%
Max Drawdown (1Y) Largest decline over 1 year	-44.67%	-72.26%	+27.59%
Max Drawdown (3Y) Largest decline over 3 years	-44.67%	-92.72%	+48.05%
Max Drawdown (5Y) Largest decline over 5 years	-99.01%	-92.72%	-6.29%
Max Drawdown (10Y) Largest decline over 10 years	—	-93.33%	—
Current Drawdown Current decline from peak	-45.51%	-90.91%	+45.40%
Average Drawdown Average peak-to-trough decline	-69.12%	-68.14%	-0.98%
Ulcer Index Depth and duration of drawdowns from previous peaks	24.92%	54.00%	-29.08%

Volatility

DAVE vs. SRPT - Volatility Comparison

Dave Inc. (DAVE) has a higher volatility of 19.25% compared to Sarepta Therapeutics, Inc. (SRPT) at 17.02%. This indicates that DAVE's price experiences larger fluctuations and is considered to be riskier than SRPT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DAVE	SRPT	Difference
Volatility (1M) Calculated over the trailing 1-month period	19.25%	17.02%	+2.23%
Volatility (6M) Calculated over the trailing 6-month period	48.45%	52.59%	-4.14%
Volatility (1Y) Calculated over the trailing 1-year period	73.71%	103.50%	-29.79%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	98.39%	69.81%	+28.58%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	97.37%	70.75%	+26.62%

Dividends

DAVE vs. SRPT - Dividend Comparison

Neither DAVE nor SRPT has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

DAVE vs. SRPT - Profitability Comparison

The chart below illustrates the profitability comparison between Dave Inc. and Sarepta Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

DAVE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Dave Inc. reported a gross profit of 120.00M and revenue of 147.59M. Therefore, the gross margin over that period was 81.3%.

SRPT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 730.80M. Therefore, the gross margin over that period was 0.0%.

DAVE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Dave Inc. reported an operating income of 21.15M and revenue of 147.59M, resulting in an operating margin of 14.3%.

SRPT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported an operating income of 358.43M and revenue of 730.80M, resulting in an operating margin of 49.1%.

DAVE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Dave Inc. reported a net income of 57.94M and revenue of 147.59M, resulting in a net margin of 39.3%.

SRPT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sarepta Therapeutics, Inc. reported a net income of 330.96M and revenue of 730.80M, resulting in a net margin of 45.3%.

Frequently Asked Questions

Can I hold both DAVE and SRPT in my portfolio?

DAVE and SRPT have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, DAVE or SRPT?

DAVE has higher volatility (19.25%) compared to SRPT (17.02%). In terms of maximum drawdown, DAVE dropped -99.01% vs SRPT's -98.17%.

Which has better risk-adjusted returns?

DAVE currently has the higher Sharpe Ratio (0.25 vs -0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.